Mark Fiala

Assistant Professor

Washington University School of Medicine

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Mark Fiala is an Assistant Professor at Washington University School of Medicine, USA. His research areas focus on electronic health record patient portals, adolescent oncology, and health disparities among younger patients, particularly those with multiple myeloma. Recent articles reflect his commitment to understanding treatment access, financial hardships in cancer survivorship, and innovative strategies in immunotherapy for hematological conditions.

Articles (28)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Collaborators (17)

Feng Gao

Associate Professor

Washington University in St. Louis

UNITED STATES

Mark Fiala

Research Interests

Explore related searches

Contact this professor

About

Articles (28)

High-Deductible Health Plans and Out-of-Pocket Health Care Costs Among Younger Patients With Multiple Myeloma

Benefits, Problems, and Motivations for Using the Online Patient Portal in Adolescent Oncology: Interviews With Adolescents and Parents

Disparities in Access and Utilization of Electronic Health Record Patient Portals

Disparities in Access and Utilization of Electronic Health Record Patient Portals

Returning to work after breast cancer: a longitudinal analysis of employment and financial hardship

Disparities in electronic health record patient portal activation and use among people with hematological malignancies

Germline predisposition in multiple myeloma

Incidence and survival trends in small bowel adenocarcinoma (SBA) from 2000-2019 in the United States

Memory-like NK cell differentiation, inhibitory NKG2A blockade, and improved recognition via antibody or CAR engineering combine to enhance NK cell attack against multiple myeloma

Financial Toxicity and Willingness-to-Pay for Cancer Treatment Among People With Multiple Myeloma

Treatment Access among Younger Medicaid Beneficiaries with Multiple Myeloma

Mixed-Methods Study on the Responsiveness of the Comprehensive Score for Financial Toxicity Among People With Multiple Myeloma

<italic>LINC01432 </italic>binds to CELF2 in newly diagnosed multiple myeloma promoting short progression-free survival to standard therapy

A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma

A structured oral chemotherapy teaching tool to improve adherence in adults with multiple myeloma: A pilot randomized controlled trial

From criteria to clinic: How updated SLiM CRAB criteria influence multiple myeloma diagnostic activity

Use of the Current Standard of Practice Serum Free Light Chains (sFLC) Reference Interval Puts Black Patients at 5 Times Higher Odds for Light Chain Monoclonal Gammopathy of Undetermined Significance (LC-MGUS)

Patient portal recruitment may exacerbate underrepresentation in clinical trial participants

Phase I-II Trial of Early Azacitidine after Matched Unrelated Donor Hematopoietic Cell Transplantation

Venous Thromboembolism Risk in Patients With Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination With Lenalidomide and Dexamethasone

A Single Reference Interval for Interpreting Serum Free Light Chains across Patients with Varying Renal Function

Dynamic frailty risk assessment among older adults with multiple myeloma: A population-based cohort study

Evaluation of the Simplified Score to Predict Early Relapse in Multiple Myeloma (S-ERMM) in the MMRF CoMMpass study

The Dynamics of Financial Toxicity in Multiple Myeloma

Continuous Elotuzumab, Pomalidomide, and Dexamethasone Maintenance Following Second Autologous Transplantation for Multiple Myeloma: Results of a Prospective Phase 2 Multicenter Trial

Duvelisib for Critically Ill Patients With Coronavirus Disease 2019: An Investigator-Initiated, Randomized, Placebo-Controlled, Double-Blind Pilot Trial

Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma

Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis

Collaborators (17)

Feng Gao

Keith Stockerl-Goldstein

Kristen Sanfilippo

Bryan Sisk

Su-Hsin Chang

John L. Frater

Craig Hofmeister

Matthew LeBlanc

Hamlet Gasoyan

Swati Bhasin

Yohita Shraddha Bandaru

Leah Gehrs

Shi-Yi Wang

Michael Slade

Jaebok Choi

Theresa Coles

Ajay Major

Make your next move.